Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pioglitazone + imatinib
- Development stage
- Phase 2
- Lead developer
- Centre Hospitalier de Versailles
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of pioglitazone and imatinib is an investigational therapeutic regimen for chronic myeloid leukemia (CML), specifically evaluated in the ACTIM Phase II clinical trial sponsored by Versailles Hospital (Centre Hospitalier de Versailles). Pioglitazone, a thiazolidinedione traditionally used for type 2 diabetes, acts as a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ). In the context of CML, pioglitazone is used as an add-on therapy to the tyrosine kinase inhibitor (TKI) imatinib to target residual disease. The mechanism involves the downregulation of STAT5 transcription, which pulls quiescent CML stem cells out of their protective dormant state and sensitizes them to the pro-apoptotic effects of imatinib. This combination aims to achieve deeper molecular responses (such as MR4.5) in patients who have achieved a major molecular response but still harbor residual leukemic clones.
- Brand names
- Actos + GleevecActos + Glivec
- Other names
- pioglitazone add-on therapypioglitazone + imatinib mesylate
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)PDGFR (PDGFR family)PPARG (Peroxisome proliferator-activated receptor gamma)STAT5A (STAT5)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on pioglitazone + imatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pioglitazone + imatinib.